MA39228A1 - Compositions à utiliser pour le traitement d'états allergiques - Google Patents

Compositions à utiliser pour le traitement d'états allergiques

Info

Publication number
MA39228A1
MA39228A1 MA39228A MA39228A MA39228A1 MA 39228 A1 MA39228 A1 MA 39228A1 MA 39228 A MA39228 A MA 39228A MA 39228 A MA39228 A MA 39228A MA 39228 A1 MA39228 A1 MA 39228A1
Authority
MA
Morocco
Prior art keywords
compositions
allergic conditions
treating allergic
treating
conditions
Prior art date
Application number
MA39228A
Other languages
English (en)
Inventor
Steven G Reed
Christopher H Clegg
Christopher Arendt
Alexandra Kropotova
Kurt Stoeckli
Original Assignee
Immune Design Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52462439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39228(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immune Design Corp filed Critical Immune Design Corp
Publication of MA39228A1 publication Critical patent/MA39228A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/35—Allergens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

La présente invention concerne des compositions et des méthodes pour le traitement d'états allergiques, par administration d'une composition d'adjuvants, avec ou sans allergène
MA39228A 2014-01-21 2015-01-20 Compositions à utiliser pour le traitement d'états allergiques MA39228A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461929780P 2014-01-21 2014-01-21
PCT/US2015/012003 WO2015112485A1 (fr) 2014-01-21 2015-01-20 Compositions à utiliser pour le traitement d'états allergiques

Publications (1)

Publication Number Publication Date
MA39228A1 true MA39228A1 (fr) 2017-06-30

Family

ID=52462439

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39228A MA39228A1 (fr) 2014-01-21 2015-01-20 Compositions à utiliser pour le traitement d'états allergiques

Country Status (19)

Country Link
US (1) US20160030459A1 (fr)
EP (1) EP3096764A1 (fr)
JP (1) JP2017502977A (fr)
KR (1) KR20160105813A (fr)
CN (1) CN105960241A (fr)
AU (1) AU2015209575A1 (fr)
BR (1) BR112016016672A2 (fr)
CA (1) CA2935722A1 (fr)
CL (1) CL2016001843A1 (fr)
CR (1) CR20160369A (fr)
EA (1) EA201691452A1 (fr)
HK (1) HK1225994A1 (fr)
IL (1) IL246587A0 (fr)
MA (1) MA39228A1 (fr)
MX (1) MX2016009464A (fr)
PH (1) PH12016501434A1 (fr)
SG (1) SG11201605883UA (fr)
TW (1) TW201620524A (fr)
WO (1) WO2015112485A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101858840B1 (ko) * 2016-01-15 2018-05-16 단국대학교 천안캠퍼스 산학협력단 집먼지진드기 유래 알레르겐에 의한 과민반응 면역조절제
KR102464848B1 (ko) * 2016-06-16 2022-11-09 호유 가부시키가이샤 생선 알레르기의 항원
ES2997871T3 (en) 2017-12-06 2025-02-18 Prollergy Corp Composition and method for reducing allergic response
WO2021213946A1 (fr) 2020-04-19 2021-10-28 Englmeier Ludwig Prophylaxie et traitement d'infections au coronavirus
WO2026015094A1 (fr) * 2024-07-06 2026-01-15 Humanis Sağlik A.Ş. Compositions de sirop

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4286592A (en) 1980-02-04 1981-09-01 Alza Corporation Therapeutic system for administering drugs to the skin
US4314557A (en) 1980-05-19 1982-02-09 Alza Corporation Dissolution controlled active agent dispenser
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US4379454A (en) 1981-02-17 1983-04-12 Alza Corporation Dosage for coadministering drug and percutaneous absorption enhancer
US4411993A (en) 1981-04-29 1983-10-25 Steven Gillis Hybridoma antibody which inhibits interleukin 2 activity
US4543439A (en) 1982-12-13 1985-09-24 Massachusetts Institute Of Technology Production and use of monoclonal antibodies to phosphotyrosine-containing proteins
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
US4902614A (en) 1984-12-03 1990-02-20 Teijin Limited Monoclonal antibody to human protein C
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US4948587A (en) 1986-07-08 1990-08-14 Massachusetts Institute Of Technology Ultrasound enhancement of transbuccal drug delivery
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4780212A (en) 1987-07-31 1988-10-25 Massachusetts Institute Of Technology Ultrasound enchancement of membrane permeability
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB2232892B (en) 1988-02-23 1991-07-24 John Mark Tucker Occlusive body for administering a physiologically active substance
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
ATE115862T1 (de) 1989-02-04 1995-01-15 Akzo Nobel Nv Tocole als impfstoffadjuvans.
CA2017507C (fr) 1989-05-25 1996-11-12 Gary Van Nest Adjuvant constitue d'une emulsion de gouttelettes submicron d'huile
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
AU4662393A (en) 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
DE69418143T2 (de) 1993-11-02 1999-08-26 Matsushita Electric Industrial Co. Verfahren zur Herstellung eines Aggregats von Mikro-Nadeln aus Halbleitermaterial
US5885211A (en) 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
US5458140A (en) 1993-11-15 1995-10-17 Non-Invasive Monitoring Company (Nimco) Enhancement of transdermal monitoring applications with ultrasound and chemical enhancers
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
DE9319879U1 (de) 1993-12-23 1994-03-17 Ems-Inventa AG, Zürich Sequentiell Coextrudierte Kühlflüssigkeitsleitung
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5457041A (en) 1994-03-25 1995-10-10 Science Applications International Corporation Needle array and method of introducing biological substances into living cells using the needle array
US5591139A (en) 1994-06-06 1997-01-07 The Regents Of The University Of California IC-processed microneedles
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
EP1167379A3 (fr) 1994-07-15 2004-09-08 University Of Iowa Research Foundation Oligonucléotides immunomodulateurs
US5618275A (en) 1995-10-27 1997-04-08 Sonex International Corporation Ultrasonic method and apparatus for cosmetic and dermatological applications
US5656016A (en) 1996-03-18 1997-08-12 Abbott Laboratories Sonophoretic drug delivery system
US5762943A (en) * 1996-05-14 1998-06-09 Ribi Immunochem Research, Inc. Methods of treating type I hypersensitivity using monophosphoryl lipid A
US7033598B2 (en) 1996-11-19 2006-04-25 Intrabrain International N.V. Methods and apparatus for enhanced and controlled delivery of a biologically active agent into the central nervous system of a mammal
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
GB2336310B (en) 1998-04-14 2003-09-10 Stowic Resources Ltd Method of manufacturing transdermal patches
US6322532B1 (en) 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6685699B1 (en) 1999-06-09 2004-02-03 Spectrx, Inc. Self-removing energy absorbing structure for thermal tissue ablation
JP4162813B2 (ja) 1999-10-28 2008-10-08 久光製薬株式会社 イオントフォレーシス装置
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
US6908453B2 (en) 2002-01-15 2005-06-21 3M Innovative Properties Company Microneedle devices and methods of manufacture
US6676961B1 (en) 2002-03-06 2004-01-13 Automated Carrier Technologies, Inc. Transdermal patch assembly
US7018345B2 (en) 2002-12-06 2006-03-28 Hisamitsu Pharmaceutical Co., Inc. Iontophoresis system
US20090181078A1 (en) * 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
PL2068918T5 (pl) * 2006-09-26 2024-12-02 Access To Advanced Health Institute Kompozycja szczepionki zawierająca syntetyczny adiuwant
WO2009035528A2 (fr) 2007-09-07 2009-03-19 University Of Georgia Research Foundation, Inc. Dérivé de synthèse du lipide a
CA2764374C (fr) * 2009-06-05 2019-11-19 Infectious Disease Research Institute Adjuvants lipidiques synthetiques a base de glucopyranosyle

Also Published As

Publication number Publication date
CA2935722A1 (fr) 2015-07-30
WO2015112485A1 (fr) 2015-07-30
US20160030459A1 (en) 2016-02-04
PH12016501434A1 (en) 2016-09-14
CL2016001843A1 (es) 2017-04-28
IL246587A0 (en) 2016-08-31
JP2017502977A (ja) 2017-01-26
BR112016016672A2 (pt) 2017-08-08
MX2016009464A (es) 2017-01-16
EA201691452A1 (ru) 2016-12-30
CR20160369A (es) 2016-10-05
SG11201605883UA (en) 2016-08-30
EP3096764A1 (fr) 2016-11-30
KR20160105813A (ko) 2016-09-07
HK1225994A1 (zh) 2017-09-22
AU2015209575A1 (en) 2016-07-21
TW201620524A (zh) 2016-06-16
CN105960241A (zh) 2016-09-21

Similar Documents

Publication Publication Date Title
CY1122344T1 (el) Blautia stercosis και wexlerae για χρηση στην θεραπευτικη αγωγη φλεγμονωδων και αυτοανοσων νοσων
CY1122184T1 (el) Συνθεσεις περιλαμβανουσες βακτηριακα στελεχη
MA41013A (fr) Compositions comprenant des souches bactériennes
MY196319A (en) Polycyclic TLR7/8 Antagonists and use Thereof in the Treatment of Immune Disorders
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201891199A1 (ru) Композиции, содержащие бактериальные штаммы
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
WO2016033439A3 (fr) Compositions et méthodes pour le traitement d'une maladie ou d'un trouble inflammatoire
EA201890047A1 (ru) Композиции, содержащие бактериальные штаммы
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201890051A1 (ru) Композиции, содержащие бактериальные штаммы
PH12017500207A1 (en) Indoles for use in influenza virus infection
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201890049A1 (ru) Композиции, содержащие бактериальные штаммы
EA201990043A1 (ru) Антибактериальные соединения
EA202090683A3 (ru) Способы и композиции для лечения рака
EA201500383A1 (ru) Производные 1,2,4-триазина для лечения вирусных инфекций
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
EP3049104A4 (fr) Compositions de vaccins, adjuvants et procédés pour le traitement d'infections urinaires
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
EA201790507A1 (ru) Способы и композиции для усиления иммунных ответов
EA201690859A1 (ru) Предотвращение инфекций, вызываемых staphylococcus aureus, гликопротеиновыми вакцинами, синтезированными в escherichia coli
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
MA39228A1 (fr) Compositions à utiliser pour le traitement d'états allergiques